Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
Please note that Amgen’s approved corporate descriptions are subject to periodic updates. To obtain the latest version of this corporate description, please visit the Communication Materials and Tools page on MyAmgen.
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Twentynine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines.
Founded in 1896, the Roche Group is headquartered in Basel, Switzerland, and is active in over 100 countries. In 2016 Roche employed more than 94,00 people worldwide and invested CHF 9.9 billion in research and development, including almost AUD 37 million in pharmaceuticals in Australia.
Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry eight years in a row by the Dow Jones Sustainability Indices.
Roche’s pharmaceutical division in Australia is dedicated to the clinical development, registration, sales, marketing and distribution of innovative pharmaceutical medicines. Australian patients have access to about 40 Roche medicines, and the company is the leading provider of cancer medicines in
Australia by sales.
Fresenius Medical Care, The Renal Company, is the world’s largest intergraded manufacturer and provider of products, therapies and services for renal patients.
We care for nearly 310,000 patients in our global network of more than 3,600 dialysis clinics. At the same time, we operate 37 production sites on all continents, to provide dialysis products such as dialysis machines, dialysers, PD fluids and related disposables.
As the largest provider of dialysis care in Australia, we intimately understand the impact chronic kidney failure has on people’s lives. We are committed to delivering outstanding patient care that goes beyond innovative dialysis products and therapies. We care for each individual patients situation, whether they wish to perform dialysis at home or receive dialysis within one of our 18 clinics across the country. Our ability to deliver excellent patient outcomes is due to the quality and professionalism of over 350 full and part time nursing staff we employ across Australia, who provide dialysis to around 800 patients. Our nursing teams share our passion for creating a future worth living for every one of our patients.
For nearly half a century we have been helping patients with end stage renal disease live fuller, richer and more active lives. We are committed to life, to life-changing outcomes, everything renal.
Baxter’s renal business is committed to addressing the individual needs of renal patients by providing innovative products, therapies, support and services that are designed to improve their health-related quality-of-life. Baxter has over 60 years of experience in renal care starting in 1956 with the introduction of the world’s first commercial dialysis system. Today, Baxter Healthcare continues to invest in cutting edge technology in Haemodialysis, Peritoneal Dialysis and Acute Kidney Failure reflecting our commitment to advancing and simplifying dialysis. We continue to expand our R & D and manufacturing capacity to meet the healthcare professional’s growing demand for smarter dialysis systems that save and sustain patient’s lives.
Otsuka Australia Pharmaceutical Pty Ltd was established in 2014 with the aim of bringing innovative medicines to Australian patients. In nephrology, Otsuka has a focus on autosomal dominant polycystic kidney disease (ADPKD) and anemia associated with chronic kidney disease (CKD).
In Australia, Otsuka provides treatments for kidney diseases, central nervous system disorders, cardiovascular diseases and cancer.
Globally, the Company has a proud history dating back to its beginnings in Japan in 1921 and, as a research-based discovery organization, has a pipeline of new treatments in areas of high unmet clinical need. ‘Otsuka-people creating new products for better health worldwide,’ embodies the company’s dedication to creating innovative products and improving health and well-being.
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. We have more than 60 years’ history in Australia and employ around 800 associates across our three divisions. We believe continued R&D is essential to innovation and in Australia we invest around 20M annually in local clinical trials. Our mission is to discover new ways to improve and extend people’s lives.
To find out more about Novartis in Australia visit the website:
NAME BADGE & LANYARD SPONSOR
PAD & PEN SPONSOR
AstraZeneca is the third largest pharmaceutical company operating in Australia, is one of the country’s largest manufacturers of medicines and is a key exporter to 30 international markets. AstraZeneca produces medicines in a range of therapeutic areas including cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca contributes significantly to clinical trials in Australia with approximately 50 concurrent trials. AstraZeneca’s innovative medicines are used by millions of patients worldwide. For more information please visit www.astrazeneca.com.au
Ortho Clinical Diagnostics is a leading global provider of in vitro diagnostics. We have an established track record for providing high-quality products and services to the global clinical laboratory and immunohematology communities. We are proud to introduce a new test allowing clinicians to assess and predict a patients potential risk of AKI – NephroCheck.
Sanofi, a world leader in Life Science, committed to prevention and treatment of disease and to supporting populations throughout the world.
We are Sanofi, we live for life. By partnering with patients we can find new ways of helping them feel better, live longer, keep healthy and stay stronger.
The aim of Kidney Health Australia – Caring for Australasians with Renal Impairment (KHA-CARI) is to improve the health care and outcomes of paediatric and adult patients with kidney disease by helping clinicians and health care workers to adhere to evidence-based clinical practice as often as possible.
Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare diseases. Our global headquarters and research operations are in New Haven, Conn. Alexion’s approximately 3,000 employees around the world serve patients in 50 countries.
Kidney Health Australia is the national peak body for kidney disease, and promotes good kidney health though education, advocacy, research and support. A not-for-profit organisation dedicated to helping people with kidney disease, to improve their health outcomes and quality of life, and that of their families and carers.
For more than a century, Merck, a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world – including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer’s disease and infectious diseases including HIV and Ebola. For more information, visit www.merck.com and connect with us on Twitter, Facebook, Instagram, YouTube and LinkedIn.